Logo

NTLA

Intellia Therapeutics, Inc.

NTLA

Intellia Therapeutics, Inc. • NASDAQ
$8.99 ▲ 5.52% (+0.47)
Market Cap $942.03 M
52w High $28.25
52w Low $5.90
Dividend Yield 0%
P/E -2.12
Volume 3.71M
Outstanding Shares 104.79M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $13.782M ▼ $46.31M ▼ $-101.324M ▼ -735.191% ▼ $-0.92 ▲ $-96.388M ▲
Q2-2025 $14.245M ▼ $124.241M ▼ $-101.255M ▲ -710.811% ▼ $-0.98 ▲ $-107.522M ▲
Q1-2025 $16.627M ▲ $137.434M ▼ $-114.329M ▲ -687.611% ▲ $-1.1 ▲ $-118.309M ▲
Q4-2024 $12.874M ▲ $149.321M ▼ $-128.898M ▲ -1.001K% ▲ $-1.27 ▲ $-133.881M ▲
Q3-2024 $9.111M $153.881M $-135.712M -1.49K% $-1.34 $-142.162M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $511.044M ▲ $925.275M ▲ $176.853M ▼ $748.422M ▲
Q2-2025 $459.651M ▼ $898.894M ▼ $183.639M ▼ $715.255M ▼
Q1-2025 $503.747M ▼ $986.163M ▼ $206.244M ▼ $779.919M ▼
Q4-2024 $601.515M ▼ $1.191B ▲ $319.059M ▲ $871.956M ▼
Q3-2024 $658.114M $1.173B $210.736M $962.615M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $-101.324M ▼ $-76.899M ▲ $-741K ▼ $114.857M ▲ $37.217M ▲ $-76.928M ▲
Q2-2025 $-101.255M ▲ $-99.622M ▲ $106.91M ▲ $14.652M ▲ $21.94M ▲ $-99.861M ▲
Q1-2025 $-114.329M ▲ $-148.93M ▼ $94.328M ▼ $0 ▼ $-54.602M ▼ $-149.665M ▼
Q4-2024 $-128.898M ▲ $-85.195M ▼ $151.565M ▲ $2.317M ▼ $68.687M ▲ $-86.176M ▼
Q3-2024 $-135.712M $-84.837M $-7.709M $82.192M $-10.354M $-86.116M

Five-Year Company Overview

Income Statement

Income Statement Intellia is still very much a research-stage company: revenue is tiny and irregular, largely from partnerships rather than product sales. Operating losses are large and have grown meaningfully over the last several years, driven by heavy spending on research, clinical trials, and supporting infrastructure. Net losses per share have deepened compared with the early years after IPO, though they appear to have stopped worsening and have slightly improved versus the peak loss period. Overall, the business model today is “spend heavily on science, with little offsetting revenue yet.”

Balance Sheet

Balance Sheet The balance sheet shows a company that has built up a sizable asset base and equity cushion over time, helped by past financings and collaborations, but with some gradual erosion more recently. Cash was strongest a few years ago and has since trended down as the company funds its pipeline. Debt remains modest relative to total assets and equity, so the capital structure is not highly leveraged. However, with equity drifting down and debt inching up from very low levels, the financial flexibility is still good but not unlimited, especially if losses continue at the current pace.

Cash Flow

Cash Flow Cash flow is consistently negative, reflecting ongoing investment in R&D and clinical programs. Operating cash outflows have grown significantly compared with several years ago, and free cash flow is also firmly negative, indicating the company depends on external funding sources and partnerships to extend its runway. Capital spending is relatively small, so the vast majority of the cash burn comes from operating activities rather than big physical investments. This is typical for a biotech focused on science rather than manufacturing at scale, but it means the sustainability of the current strategy hinges on access to new capital or milestone payments.

Competitive Edge

Competitive Edge Intellia holds a prominent scientific position in CRISPR-based gene editing, especially in therapies that edit genes directly inside the body. Its delivery technology, strong academic roots, and high-profile scientific founders provide credibility. The collaboration with a large pharmaceutical partner adds development expertise and some financial backing. At the same time, the competitive field in gene editing is crowded, with multiple well-funded peers working on overlapping targets and technologies. The patent landscape is complex and occasionally litigious, creating uncertainty around how durable any one company’s advantage will be. The recent regulatory setback for a lead program also weakens near‑term positioning and gives rivals a chance to catch up or pull ahead in specific indications.

Innovation and R&D

Innovation and R&D Innovation is clearly the core of Intellia’s identity. The company is pushing the frontier in in vivo CRISPR editing, exploring newer tools like base editing and DNA writing, and running both in vivo and ex vivo programs across genetic and immune-related diseases. R&D spending is heavy relative to revenue, consistent with its ambition to build a broad, modular platform rather than a single product. The pipeline includes late-stage programs that, if successful, could be transformative for patients and the company. However, the FDA hold on a flagship program, the decision to discontinue another candidate, and a recent reorganization and workforce reduction show that the path of innovation is bumpy and requires constant reprioritization of resources and risk.

Summary

Financially, Intellia looks like a classic high‑science, pre-commercial biotech: minimal revenue, substantial and persistent losses, and steady cash burn, supported by a still-solid but slowly shrinking cash and equity base. Strategically, it sits at the cutting edge of CRISPR gene editing with meaningful scientific and partnering strengths, but also faces intense competition, legal and regulatory complexity, and elevated clinical risk, now highlighted by the recent trial hold and program changes. Future outcomes hinge on successful clinical readouts, resolution of regulatory issues, continued access to capital, and the company’s ability to convert its strong research engine into approved, commercially viable therapies over time.

NEWS

November 10, 2025 · 3:17 PM UTC

Intellia Therapeutics Presents Positive Longer-Term Phase 1 Data of Nexiguran Ziclumeran (nex-z) in Patients with Transthyretin (ATTR) Amyloidosis with Cardiomyopathy

Read more

November 8, 2025 · 5:13 PM UTC

Intellia Therapeutics Presents Positive Pooled Phase 1/2 Data of Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema

Read more

October 27, 2025 · 7:30 AM UTC

Intellia Therapeutics Provides Update on MAGNITUDE Clinical Trials of Nexiguran Ziclumeran (nex-z)

Read more

October 3, 2025 · 4:01 PM UTC

Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Read more

September 25, 2025 · 9:52 AM UTC

Intellia Therapeutics Announces Positive Longer-Term Phase 1 Data for Nexiguran Ziclumeran (nex-z) in Patients with Hereditary Transthyretin (ATTR) Amyloidosis with Polyneuropathy

Read more